Quince Therapeutics board overhaul: 3 directors to resign, 4 named pending Oct 6 vote

Quince Therapeutics, Inc.

Directors June Bray, David Lamond and Christopher Senner conditionally resigned effective two business days after the Oct 6, 2026 Special Meeting; no disagreement with the Company cited.
Board seats contingent on approval of three proposals: Series C conversion (>20% of shares outstanding), Minimum Price Proposal, and raising authorized shares from 250M to 275M.
Incoming directors: Catherine Bonuccelli (Class I; Audit, Comp), Leone Patterson (Class III; chair Audit & Comp), James Valentine (Class I; chair NomGov), Drayton Wise (Class II; NomGov).
Conversion Proposal may, together with certain management and board changes, result in a change of control under Nasdaq Listing Rule 5635(b).
Incoming directors' backgrounds: Bonuccelli ex-Bellus Health CMO; Patterson ex-CFO Zymeworks and Tenaya; Wise ex-CCO Insmed; Valentine director at Hyman, Phelps & McNamara.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.